Samlyn Capital, LLC Corvus Pharmaceuticals, Inc. Transaction History
Samlyn Capital, LLC
- $6.21 Billion
- Q4 2024
A detailed history of Samlyn Capital, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Samlyn Capital, LLC holds 6,667,105 shares of CRVS stock, worth $26.3 Million. This represents 0.56% of its overall portfolio holdings.
Number of Shares
6,667,105
Previous 4,530,333
47.17%
Holding current value
$26.3 Million
Previous $23.9 Million
44.93%
% of portfolio
0.56%
Previous 0.39%
Shares
7 transactions
Others Institutions Holding CRVS
# of Institutions
102Shares Held
38.1MCall Options Held
2.75MPut Options Held
1.17M-
Orbimed Advisors LLC San Diego, CA6.94MShares$27.4 Million0.98% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$12.9 Million18.22% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.03MShares$11.9 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$10.6 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.45MShares$9.67 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $183M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...